2025-07-26 - Analysis Report
Okay, here's a comprehensive analysis of Merck & Co. Inc. (MRK), presented in English with numbers first, followed by analysis.

## MRK Stock Analysis

### 1. Performance vs. S&P 500 (VOO)

*   **Ticker:** MRK
*   **Company:** Merck & Co Inc
*   **Description:** A global pharmaceutical company known for its innovative medicines and vaccines.
*   **MRK Cumulative Return:** -3.23%
*   **VOO Cumulative Return:** 99.66%
*   **Relative Divergence:**
    *   Max: 23.1
    *   Min: -102.3
    *   Current: -101.5
    *   Relative Divergence (% of Range): 0.6%

**Analysis:** MRK has significantly underperformed the S&P 500 (VOO) over the period examined. The current relative divergence of -101.5 indicates that MRK is near its historical low relative to the S&P 500. The relative divergence percentage of 0.6% suggests MRK's performance is at the very bottom end of its historical range compared to the S&P 500.

#### Alpha, Beta Analysis:

| Year       | CAGR     | MDD      | Alpha     | Beta   | Cap (B) |
| :--------- | :------- | :------- | :-------- | :----- | :------ |
| 2015-2017  | 5.0%     | 58.2%    | -24.0%    | -0.0   | 134.8   |
| 2016-2018  | 43.0%    | 66.4%    | 25.0%     | -0.1   | 183.1   |
| 2017-2019  | 40.0%    | 66.4%    | 11.0%     | 0.3    | 217.9   |
| 2018-2020  | 20.0%    | 66.4%    | 0.0%      | 0.3    | 196.0   |
| 2019-2021  | -1.0%    | 65.6%    | -50.0%    | 0.3    | 192.4   |
| 2020-2022  | 13.0%    | 69.5%    | 11.0%     | 0.3    | 278.6   |
| 2021-2023  | 31.0%    | 69.5%    | 13.0%     | 0.3    | 273.8   |
| 2022-2024  | -7.0%    | 69.5%    | -33.0%    | 0.2    | 249.8   |
| 2023-2025  | -55.0%   | 61.4%    | -107.0%   | 0.5    | 212.7   |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** Fluctuates significantly, with recent periods showing negative growth (-7%, -55%).
*   **MDD (Maximum Drawdown):** High, ranging from 58.2% to 69.5%, indicating substantial potential losses.
*   **Alpha:** Generally negative, especially in recent years (-33%, -107%), suggesting underperformance relative to its benchmark.
*   **Beta:** Positive but relatively low (0.2-0.5), implying slightly higher volatility than the market.
*   **Market Capitalization:** Decreasing Market Capitalization from 2020-2025

### 2. Recent Stock Price Movement

*   **Current Price:** $84.71
*   **Previous Close:** $84.11
*   **Change:** $0.71
*   **5-Day Moving Average:** 82.74
*   **20-Day Moving Average:** 81.95
*   **60-Day Moving Average:** 79.84

**Analysis:** The stock price is above all its moving averages (5, 20, and 60-day), suggesting a short-term upward trend. The recent price increase of $0.71 suggests positive momentum.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.33 (Low Risk)
*   **RSI (Relative Strength Index):** 62.16
*   **PPO (Percentage Price Oscillator):** 0.22
*   **Hybrid Signal:** cash_3%_Buy 80% of cash (160 shares - Caution - MRI:0.33)
*   **Recent (20-day) Relative Divergence Change:** -1.3 (Negative, indicates short-term decline)
*   **Expected Return (%):** -1129.2%

**Analysis:**

*   **MRI:** Indicates low market risk.
*   **RSI:** At 62.16, the stock is approaching overbought territory (above 70).
*   **PPO:** Positive PPO suggests upward momentum, but relatively low.
*   **Hybrid Signal:** Advises to buy 80% of cash with caution, considering the low MRI.
*   **Relative Divergence Change:** The recent decline in relative divergence signals short-term weakness.
*   **Expected Return:** The very negative expected return indicates a long-term negative outlook compared to the S&P 500.
* **Price Change:** The price change of $0.71 reflecting recent change in Market

### 4. Recent News & Significant Events

*   **[2025-07-24]:** Major business developments, regulatory changes, or market events.
*   **[2025-07-22]:** Analyst discussions regarding performance and outlook.
*   **[2025-07-23]:** Notable stock volatility.
*   **[2025-07-25]:** Market experts highlighting risks and opportunities.

**Analysis:** Recent news suggests potential volatility and significant events influencing MRK's stock. Investors should monitor these events closely.

### 5. Recent Earnings Analysis:

| Date       | EPS  | Revenue     |
| :--------- | :--- | :---------- |
| 2025-05-02 | 2.01 | $15.53B     |
| 2024-11-06 | 1.25 | $16.66B     |
| 2024-08-05 | 2.15 | $16.11B     |
| 2024-05-03 | 1.88 | $15.78B     |
| 2025-05-02 | 1.88 | $15.78B     |

**Analysis:**

*   Earnings Per Share (EPS) have fluctuated over the past quarters.
*   Revenue has shown some variability, but is generally consistent in the $15-17 billion range.

### 6. Financial Information:

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
| :----------- | :------- | :------------ |
| 2025-03-31   | $15.53B  | 77.98%        |
| 2024-12-31   | $15.62B  | 75.50%        |
| 2024-09-30   | $16.66B  | 75.51%        |
| 2024-06-30   | $16.11B  | 76.76%        |
| 2024-03-31   | $15.78B  | 77.56%        |

**Capital and Profitability:**

| Quarter      | Equity   | ROE      |
| :----------- | :------- | :------- |
| 2025-03-31   | $48.34B  | 10.51%   |
| 2024-12-31   | $46.31B  | 8.08%    |
| 2024-09-30   | $44.50B  | 7.09%    |
| 2024-06-30   | $43.58B  | 12.52%   |
| 2024-03-31   | $40.36B  | 11.80%   |

**Analysis:**

*   **Revenue:** Relatively stable over the past quarters.
*   **Profit Margin:** Consistently high, indicating strong profitability.
*   **Equity:** Increasing over time.
*   **ROE (Return on Equity):** Fluctuates, suggesting variations in profitability relative to shareholder equity.

### 7. Overall Summary

Merck & Co. (MRK) exhibits a mixed outlook:

*   **Underperformance:** MRK has significantly underperformed the S&P 500 recently.
*   **Technical Signals:** While recent price movement shows short-term upward momentum, the RSI is approaching overbought levels, and recent divergence changes suggest potential weakness.
*   **Financials:** Strong profit margins and increasing equity are positive, but ROE fluctuations indicate variability.
*   **News:** Recent news points to significant events influencing the stock, warranting close monitoring.
*   **Risk:** While MRI indicates low market risk, the negative expected return suggests caution for long-term investment.

**Recommendation:** Given the underperformance, recent negative trends, and news volatility, a cautious approach is advised. Investors should carefully weigh the positive financial aspects against the risks and monitor upcoming news and events closely before making any decisions.
